MedTrace Logo

Metatranscriptomic Next Generation Sequencing in First Trimester Trophoblast With Increased Fetal Nuchal Translucency (METAHCN)

NCT05388968 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 110

Last updated 2024-05-03

No results posted yet for this study

Summary

The study is based on the hypothesis that increased nuchal translucency may be associated with a materno fetal infection and that the pathogen responsible for this infection could be identify with metatranscriptomic next-generation sequencing in the trophoblast tissue.

Conditions

  • Increased Nuchal Translucency in the First Trimester of Pregnancy

Interventions

BIOLOGICAL

Metatranscriptomic

Analysis with metatranscriptomic next generation sequencing of trophoblast obtained by chorionic villi sampling

DIAGNOSTIC_TEST

Specific microbiologic diagnosis

If a microorganism is detected by metatranscriptomic NGS, specific diagnosis (PCR and serology) will be done in maternal and neonatal samples (blood, urine, saliva)

Sponsors & Collaborators

  • Pathogen Discovery Laboratory

    collaborator UNKNOWN

  • Institut Pasteur

    collaborator INDUSTRY

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Marianne LERUEZ-VILLE, MD, PhD · Assistance Publique - Hôpitaux de Paris

  • Yves Ville, MD, PhD · Assistance Publique - Hôpitaux de Paris

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-07
Primary Completion
2025-05-31
Completion
2026-02-28

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05388968 on ClinicalTrials.gov